Viz.ai Secures FDA De Novo Clearance for AI-Enabled Detection of Heart Disease
Viz.ai gains FDA De Novo approval for its AI-driven algorithm detecting hypertrophic cardiomyopathy (HCM). This breakthrough software evaluates electrocardiograms, alerting specialists to suspicious findings for further assessment. The FDA’s recognition establishes a new category…
Continue Reading